Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.49
QGEN's Cash to Debt is ranked higher than
55% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. QGEN: 0.49 )
QGEN' s 10-Year Cash to Debt Range
Min: 0.34   Max: 3.38
Current: 0.49

0.34
3.38
Equity to Asset 0.60
QGEN's Equity to Asset is ranked higher than
71% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. QGEN: 0.60 )
QGEN' s 10-Year Equity to Asset Range
Min: 0.47   Max: 0.72
Current: 0.6

0.47
0.72
Interest Coverage 4.09
QGEN's Interest Coverage is ranked lower than
51% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. QGEN: 4.09 )
QGEN' s 10-Year Interest Coverage Range
Min: 2.05   Max: 53.96
Current: 4.09

2.05
53.96
F-Score: 7
Z-Score: 3.15
M-Score: -2.65
WACC vs ROIC
7.37%
5.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.83
QGEN's Operating margin (%) is ranked higher than
88% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. QGEN: 11.83 )
QGEN' s 10-Year Operating margin (%) Range
Min: 4.86   Max: 23.8
Current: 11.83

4.86
23.8
Net-margin (%) 8.66
QGEN's Net-margin (%) is ranked higher than
88% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. QGEN: 8.66 )
QGEN' s 10-Year Net-margin (%) Range
Min: 5.31   Max: 15.62
Current: 8.66

5.31
15.62
ROE (%) 4.35
QGEN's ROE (%) is ranked higher than
78% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.68 vs. QGEN: 4.35 )
QGEN' s 10-Year ROE (%) Range
Min: 2.49   Max: 20.73
Current: 4.35

2.49
20.73
ROA (%) 2.67
QGEN's ROA (%) is ranked higher than
80% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. QGEN: 2.67 )
QGEN' s 10-Year ROA (%) Range
Min: 1.65   Max: 14.11
Current: 2.67

1.65
14.11
ROC (Joel Greenblatt) (%) 23.25
QGEN's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. QGEN: 23.25 )
QGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.39   Max: 47.81
Current: 23.25

9.39
47.81
Revenue Growth (3Y)(%) 6.70
QGEN's Revenue Growth (3Y)(%) is ranked higher than
76% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. QGEN: 6.70 )
QGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.2   Max: 44.5
Current: 6.7

-2.2
44.5
EBITDA Growth (3Y)(%) 9.30
QGEN's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. QGEN: 9.30 )
QGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.1   Max: 48.8
Current: 9.3

-9.1
48.8
EPS Growth (3Y)(%) 8.60
QGEN's EPS Growth (3Y)(%) is ranked higher than
81% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. QGEN: 8.60 )
QGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -22.5   Max: 47.4
Current: 8.6

-22.5
47.4
» QGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

QGEN Guru Trades in Q2 2014

PRIMECAP Management 22,087,404 sh (-0.66%)
Manning & Napier Advisors, Inc 2,251,855 sh (-48.91%)
Jim Simons 372,000 sh (-63.82%)
» More
Q3 2014

QGEN Guru Trades in Q3 2014

PRIMECAP Management 22,080,114 sh (-0.03%)
Manning & Napier Advisors, Inc 2,226,305 sh (-1.13%)
Jim Simons 217,000 sh (-41.67%)
» More
Q4 2014

QGEN Guru Trades in Q4 2014

PRIMECAP Management 22,284,066 sh (+0.92%)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 2,224,435 sh (-0.08%)
» More
Q1 2015

QGEN Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 2,162,732 sh (-2.77%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 62.70
QGEN's P/E(ttm) is ranked higher than
73% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 62.70 )
QGEN' s 10-Year P/E(ttm) Range
Min: 23.18   Max: 149.99
Current: 62.7

23.18
149.99
Forward P/E 19.84
QGEN's Forward P/E is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 19.84 )
N/A
PE(NRI) 62.80
QGEN's PE(NRI) is ranked higher than
80% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 62.80 )
QGEN' s 10-Year PE(NRI) Range
Min: 23.26   Max: 147.91
Current: 62.8

23.26
147.91
P/B 2.60
QGEN's P/B is ranked higher than
80% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. QGEN: 2.60 )
QGEN' s 10-Year P/B Range
Min: 1.19   Max: 2.61
Current: 2.6

1.19
2.61
P/S 4.46
QGEN's P/S is ranked higher than
55% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. QGEN: 4.46 )
QGEN' s 10-Year P/S Range
Min: 2.8   Max: 5.68
Current: 4.46

2.8
5.68
PFCF 32.30
QGEN's PFCF is ranked higher than
81% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 32.30 )
QGEN' s 10-Year PFCF Range
Min: 19.02   Max: 96.08
Current: 32.3

19.02
96.08
POCF 21.12
QGEN's POCF is ranked higher than
86% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 21.12 )
QGEN' s 10-Year POCF Range
Min: 11.72   Max: 49.27
Current: 21.12

11.72
49.27
EV-to-EBIT 48.37
QGEN's EV-to-EBIT is ranked higher than
77% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 48.37 )
QGEN' s 10-Year EV-to-EBIT Range
Min: 17.4   Max: 100.8
Current: 48.37

17.4
100.8
PEG 314.00
QGEN's PEG is ranked higher than
88% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 314.00 )
QGEN' s 10-Year PEG Range
Min: 2.08   Max: 91.3
Current: 314

2.08
91.3
Shiller P/E 60.50
QGEN's Shiller P/E is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 60.50 )
QGEN' s 10-Year Shiller P/E Range
Min: 24.16   Max: 63.34
Current: 60.5

24.16
63.34
Current Ratio 2.66
QGEN's Current Ratio is ranked higher than
72% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. QGEN: 2.66 )
QGEN' s 10-Year Current Ratio Range
Min: 1.65   Max: 5.86
Current: 2.66

1.65
5.86
Quick Ratio 2.35
QGEN's Quick Ratio is ranked higher than
73% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. QGEN: 2.35 )
QGEN' s 10-Year Quick Ratio Range
Min: 1.36   Max: 5.31
Current: 2.35

1.36
5.31
Days Inventory 99.24
QGEN's Days Inventory is ranked higher than
74% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.68 vs. QGEN: 99.24 )
QGEN' s 10-Year Days Inventory Range
Min: 94.09   Max: 296.11
Current: 99.24

94.09
296.11
Days Sales Outstanding 76.52
QGEN's Days Sales Outstanding is ranked higher than
73% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. QGEN: 76.52 )
QGEN' s 10-Year Days Sales Outstanding Range
Min: 46.36   Max: 76.79
Current: 76.52

46.36
76.79

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 191.00
QGEN's Price/Tangible Book is ranked lower than
60% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. QGEN: 191.00 )
QGEN' s 10-Year Price/Tangible Book Range
Min: 9.2   Max: 117.83
Current: 191

9.2
117.83
Price/DCF (Projected) 2.00
QGEN's Price/DCF (Projected) is ranked higher than
89% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 2.00 )
QGEN' s 10-Year Price/DCF (Projected) Range
Min: 1.03   Max: 1.77
Current: 2

1.03
1.77
Price/Median PS Value 1.40
QGEN's Price/Median PS Value is ranked higher than
69% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. QGEN: 1.40 )
QGEN' s 10-Year Price/Median PS Value Range
Min: 0.74   Max: 1.16
Current: 1.4

0.74
1.16
Price/Graham Number 22.00
QGEN's Price/Graham Number is ranked higher than
76% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. QGEN: 22.00 )
QGEN' s 10-Year Price/Graham Number Range
Min: 4.14   Max: 18.44
Current: 22

4.14
18.44
Earnings Yield (Greenblatt) 2.10
QGEN's Earnings Yield (Greenblatt) is ranked higher than
71% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. QGEN: 2.10 )
QGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 5.7
Current: 2.1

1
5.7
Forward Rate of Return (Yacktman) -3.80
QGEN's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. QGEN: -3.80 )
QGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.2   Max: 13.9
Current: -3.8

-4.2
13.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0H1Z.UK, QIA.Germany,
Qiagen NV provides Sample & Assay Technologies, based on market studies of United States and European market shares for its products and technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics. The Company markets more than 500 core products that are distributed in thousands of variations and combinations. In October 2012, the company announced a collaboration with Bayer HealthCare for development and commercialization of companion diagnostics paired with novel Bayer drugs, initially to enhance the treatment of various solid tumors. The Company has developed and advanced a broad range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue. It has also developed assays that enable the analysis of various kinds of molecules from virtually any biological sample. Assay technologies make information contained in isolated molecules visible and available for interpretation. The Company sells varied and flexible workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases. The Company markets its products in more than 100 countries throughout the world. The Company's competitors includes Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for protein fractionation products. The Company is subject to a variety of laws and regulations in the European Union, the United States and other countries.
» More Articles for QGEN

Headlines

Articles On GuruFocus.com
comment on QGEN May 14 2013 
comment on QGEN May 10 2013 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 


More From Other Websites
Qiagen Grows on Molecular Diagnostics, Americas Disappoint - Analyst Blog Apr 20 2015
QIAGEN N.V. to Report First Quarter 2015 Results Apr 16 2015
Public tender offer on the shares of QIAGEN Marseille SA Apr 16 2015
PUBLIC TENDER OFFER ON THE SHARES OF QIAGEN MARSEILLE SA Apr 16 2015
QIAGEN Marseille announce that they have obtained the visa of the AMF on the simplified tender offer... Apr 15 2015
QIAGEN announces proposal for re-election of all current Supervisory Board members at next Annual... Apr 02 2015
QIAGEN Announces Proposal for Re-election of All Current Supervisory Board Members at Next Annual... Apr 02 2015
Can Qiagen Continue to Grow in Molecular Diagnostics Space? - Analyst Blog Apr 01 2015
Stocks to Cure What Ails on World TB Day - Analyst Blog Mar 24 2015
QIAGEN partners with leading European service provider GATC Biotech to offer clients full access to... Mar 19 2015
QIAGEN Partners With Leading European Service Provider GATC Biotech to Offer Clients Full Access to... Mar 19 2015
QIAGEN Marseille announces that its shareholders in an extraordinary general meeting voted in favor... Mar 16 2015
Tokai Pharmaceuticals Announces Expansion to Collaboration with Qiagen on the Development of an... Mar 16 2015
QIAGEN Expands Leadership in Liquid Biopsies with New Circulating Tumor Cell Technology for... Mar 16 2015
Coverage initiated on Qiagen by UBS Mar 10 2015
QIAGEN NV Financials Mar 06 2015
QIAGEN collaborates with Allele Frequency Community to advance translational medicine and clinical... Feb 24 2015
QIAGEN Collaborates With Allele Frequency Community to Advance Translational Medicine and Clinical... Feb 24 2015
QIAGEN Marseille accepts the HalioDx offer for acquisition of its assets except IP Feb 18 2015
Largest-Ever Pivotal Study in China Supports QIAGEN's QuantiFERON®-TB Gold Over Tuberculin Skin... Feb 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK